Noveris Health Sciences Inc. has become a member of BioAlberta, a non-profit association supporting Alberta's life sciences industry. This membership complements Noveris' existing collaboration with Applied Pharmaceutical Innovation (API) under a consulting agreement focused on psilocybin product development and intellectual property. Joining BioAlberta allows Noveris to engage more actively in industry events, network with other life sciences organizations, and stay updated on sector developments in Alberta. The move strengthens Noveris' presence in Alberta's life sciences ecosystem without altering its existing agreements or financial commitments.
Amazon reported strong Q2 2026 earnings, surpassing analyst expectations with an EPS of $1.88 and revenue of $200.61 billion, marking its first quarterly revenue above $200 billion. The growth was mainly fueled by a 26% increase in advertising revenu...
Top stock gainers surged due to strategic acquisitions and successful project deliveries. PN Smart Energy's shares jumped 120.80% after acquiring full equity in Nanjing Cesun Power, advancing its global power producer ambitions. T3 Defense rose 69.22...
Regional banking stocks like Coastal Financial and GBank Financial dropped sharply due to poor Q2 earnings and a legal investigation. Teladoc Health's shares fell despite beating earnings estimates, as it lowered its 2026 outlook. Inverse leveraged E...
Labcorp reported a strong second quarter in 2026, with revenue rising 5.8% to $3.73 billion and adjusted EPS increasing 14.9% to $4.99, beating analyst expectations. The company attributed growth to steady demand for testing services and expansion in...
UBS is close to completing its integration of Credit Suisse, marking a major strategic step. The bank reported strong Q2 results with net profit rising to $2.80 billion and revenues up 13.1% to $13.70 billion. Despite this, Morgan Stanley kept an Und...
